HIV clinic‐based extended‐release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non‐blinded, randomized non‐inferiority trial

• DOI: 10.1111/add.15836
• Publication Date: 2022-02-07T10:18:25Z
• Authors: P. Todd Korthuis; Ryan R. Cook; Paula J. Lum; Elizabeth Needham...; Hansel Tookes; Pamela Vergara‐Ro...; Lynn E. Kunkel; Gregory M. Lucas; Allan E. Rodriguez; Sarann Bielavitz; Laura C. Fanucchi; Kim A. Hoffman; Ken Bachrach; Elizabeth H. Payne; Julia A. Collins; Abigail Matthews; Neal Oden; Petra Jacobs; Eve Jelstrom; James L. Sorensen; Dennis McCarty
• Keywords: Intention-to-treat analysis

Opioid agonist medications for treatment of opioid use disorder (OUD) can improve human immunodeficiency virus (HIV) outcomes and reduce use. We tested whether outpatient antagonist with naltrexone could achieve similar results.